Data extracted from this reference:
Application
2.1.1.37
drug development
Dnmt inhibition is a promising strategy for the treatment of various developmental and proliferative diseases, particularly cancers
Homo sapiens
Inhibitors
2.1.1.37
2'-dC
binding modelling, overview
Homo sapiens
2.1.1.37
2'-deoxy-5-aza-cytidine
binding modelling, overview
Homo sapiens
2.1.1.37
5-azacytidine
binding modelling, overview
Homo sapiens
2.1.1.37
decitabine
binding modelling, overview
Homo sapiens
2.1.1.37
hydralazine
binding modelling, overview
Homo sapiens
2.1.1.37
additional information
inhibitor screening by molecular docking and molecular dynamics simulations
Homo sapiens
2.1.1.37
procainamide
binding modelling, overview
Homo sapiens
2.1.1.37
procaine
binding modelling, overview
Homo sapiens
Localization
2.1.1.37
nucleus
Homo sapiens
5634
Natural Substrates/ Products (Substrates)
2.1.1.37
DNA + S-adenosyl-L-methionine
Homo sapiens
DNA containing 5-methylcytosine + S-adenosyl-L-homocysteine
?
Organism
Reaction
2.1.1.37
S-adenosyl-L-methionine + DNA containing cytosine = S-adenosyl-L-homocysteine + DNA containing 5-methylcytosine
catalytic reaction mechanism of Dnmt1, overview
Homo sapiens
Substrates and Products (Substrate)
2.1.1.37
DNA + S-adenosyl-L-methionine
703228
Homo sapiens
DNA containing 5-methylcytosine + S-adenosyl-L-homocysteine
?
2.1.1.37
additional information
homology docking and molecular dynamics, overview
703228
Homo sapiens
?
Subunits
2.1.1.37
More
homology model for DNMT1 based on the template structures of the available comparable protein crystal structures, molecular dynamics, overview
Homo sapiens
Synonyms
2.1.1.37
DNA methyltransferase 1
Homo sapiens
2.1.1.37
Dnmt1
Homo sapiens
2.1.1.37
More
the enzyme belongs to the DNA methyltransferases, Dnmt, family of enzymes that methylates DNA at the C5 position of cytosine residues
Homo sapiens
Cofactor
2.1.1.37
S-adenosyl-L-methionine
Homo sapiens
Application (protein specific)
2.1.1.37
drug development
Dnmt inhibition is a promising strategy for the treatment of various developmental and proliferative diseases, particularly cancers
Homo sapiens
Cofactor (protein specific)
2.1.1.37
S-adenosyl-L-methionine
Homo sapiens
Inhibitors (protein specific)
2.1.1.37
2'-dC
binding modelling, overview
Homo sapiens
2.1.1.37
2'-deoxy-5-aza-cytidine
binding modelling, overview
Homo sapiens
2.1.1.37
5-azacytidine
binding modelling, overview
Homo sapiens
2.1.1.37
decitabine
binding modelling, overview
Homo sapiens
2.1.1.37
hydralazine
binding modelling, overview
Homo sapiens
2.1.1.37
additional information
inhibitor screening by molecular docking and molecular dynamics simulations
Homo sapiens
2.1.1.37
procainamide
binding modelling, overview
Homo sapiens
2.1.1.37
procaine
binding modelling, overview
Homo sapiens
Localization (protein specific)
2.1.1.37
nucleus
Homo sapiens
5634
Natural Substrates/ Products (Substrates) (protein specific)
2.1.1.37
DNA + S-adenosyl-L-methionine
Homo sapiens
DNA containing 5-methylcytosine + S-adenosyl-L-homocysteine
?
Substrates and Products (Substrate) (protein specific)
2.1.1.37
DNA + S-adenosyl-L-methionine
703228
Homo sapiens
DNA containing 5-methylcytosine + S-adenosyl-L-homocysteine
?
2.1.1.37
additional information
homology docking and molecular dynamics, overview
703228
Homo sapiens
?
Subunits (protein specific)
2.1.1.37
More
homology model for DNMT1 based on the template structures of the available comparable protein crystal structures, molecular dynamics, overview
Homo sapiens